# The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

> **NCT00000989** · NA · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 50 (—)

## Conditions studied

- Cytomegalovirus Retinitis
- HIV Infections

## Interventions

- **DRUG:** Zidovudine
- **DRUG:** Sargramostim
- **DRUG:** Ganciclovir

## Key facts

- **NCT ID:** NCT00000989
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1992-07
- **Target enrollment:** 50 (—)
- **Last updated:** 2021-11-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000989, "The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00000989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*